Semaglutide fails to slow Alzheimer's symptoms in large trials

Semaglutide, known for weight-loss drugs Ozempic and Wegovy, failed to slow cognitive decline in early Alzheimer's patients in two large studies. The Evoke and Evoke+ trials, involving nearly 3,800 participants, found no difference in memory or thinking skills between those taking semaglutide and those on a placebo over two years. Despite influencing some biological markers, the drug did not demonstrate a clinical benefit, leading to the discontinuation of further study extensions.